GAIN is a clinical trial evaluating whether an investigational oral drug is safe and can halt the progression of Alzheimer’s disease by reducing the damage caused by bacteria in the brain. Eligible study participants are being recruited at study sites around the country.
The GAIN Trial is based on the growing body of scientiﬁc evidence that the bacteria P. gingivalis, commonly associated with gum disease, can infect the brain and cause Alzheimer’s disease. COR388 is an investigational drug designed to inactivate toxic proteins released by the bacteria and stop or slow further damage to healthy brain cells. A study of COR388 in a small group of Alzheimer’s patients has shown promise in improving memory.